Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

By J. Baselga, J. Cortés, Sung-Bae Kim, S. Im, R. Hegg, Y. Im, L. Roman, J. Pedrini, T. Pieńkowski, A. Knott and 4 more. New England Journal of Medicine, 2011

2,419 citations recorded by the source corpus.

BACKGROUND The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody trastuzumab improves the outcome in patients with HER2-positive metastatic breast cancer. However, most cases of advanced disease eventually progress. Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the two antibodies has shown promising activity and an acceptable safety profile in phase 2 studies involving patients with HER2-positive breast cancer. METHODS We randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of toxic effects that could not be effectively managed. The primary end point was independently assessed progression-free survival. Secondary end points included overall survival, progression-free survival as assessed by the investigator, the objective response rate, and safety. RESULTS The median progression-free survival was 12.4 months in the control group, as compared with 18.5 months in the pertuzumab group (hazard ratio for progression or death, 0.62; 95% confidence interval, 0.51 to 0.75; P<0.001). The interim analysis of overall survival showed a strong trend in favor of pertuzumab plus trastuzumab plus docetaxel. The safety profile was generally similar in the two groups, with no increase in left ventricular systolic dysfunction; the rates of febrile neutropenia and diarrhea of grade 3 or above were higher in the pertuzumab group than in the control group. CONCLUSIONS The combination of pertuzumab plus trastuzumab plus docetaxel, as compared with placebo plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/ea22af44f1c38aa068c0ba406853302f8dd59cf3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014, background): “This will become an increasingly important issue in an era with a growing array of effective anti-HER2 agents available for clinical use [9–11].”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “84) No improvement 4 [91-94]”
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. (2021, background): “1 score: 3; ESCAT score: I-A].”
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 (2016, background): “Several HER2-targeting therapies such as trastuzumab (6, 7), lapatinib (8), pertuzumab (9), and T-DM1 (10) have been approved worldwide for patients with HER2-positive tumors, which are defined as either IHC 3þ or IHC 2þ/FISH– positive.”
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, positive): “1 months in patients receiving pertuzumab in addition to trastuzumab and docetaxel with minimal to no increase in cardiac toxic effects [71].”
Comprehensive molecular portraits of human breast tumors (2012, positive): “Pertuzumab, in combination with trastuzumab, targets the HER2– HER3 heterodimer 49 ; however, these data suggest that targeting EGFR with HER2 could also be beneficial.”
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) (2014, result): “The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”